Explore

Trendline Trendline
Sustained Therapeutics Reports Positive Phase 2 Results for ST-01 in Chronic Scrotal Pain Treatment

Sustained Therapeutics Reports Positive Phase 2 Results for ST-01 in Chronic Scrotal Pain Treatment

Sustained Therapeutics Reports Positive Phase 2 Results for ST-01 in Chronic Scrotal Pain Treatment
Trendline Trendline
Merck's Sac-TMT Shows Promise in Improving Survival for Endometrial Cancer Patients

Merck's Sac-TMT Shows Promise in Improving Survival for Endometrial Cancer Patients

Merck's Sac-TMT Shows Promise in Improving Survival for Endometrial Cancer Patients
Trendline Trendline
Relay Therapeutics Achieves 60% Response Rate in Rare Disease Trial, Surpassing Novartis

Relay Therapeutics Achieves 60% Response Rate in Rare Disease Trial, Surpassing Novartis

Relay Therapeutics Achieves 60% Response Rate in Rare Disease Trial, Surpassing Novartis
Trendline Trendline
Myosin Therapeutics Begins Phase 1/2 Trial of MT-125 for Glioblastoma Treatment

Myosin Therapeutics Begins Phase 1/2 Trial of MT-125 for Glioblastoma Treatment

Myosin Therapeutics Begins Phase 1/2 Trial of MT-125 for Glioblastoma Treatment
Trendline Trendline
Sumitomo Pharma America Presents Promising Vibegron Data for Older Men with Overactive Bladder

Sumitomo Pharma America Presents Promising Vibegron Data for Older Men with Overactive Bladder

Sumitomo Pharma America Presents Promising Vibegron Data for Older Men with Overactive Bladder
Trendline Trendline
Ferring Pharmaceuticals' ADSTILADRIN Shows Promise in Real-World Bladder Cancer Treatment

Ferring Pharmaceuticals' ADSTILADRIN Shows Promise in Real-World Bladder Cancer Treatment

Ferring Pharmaceuticals' ADSTILADRIN Shows Promise in Real-World Bladder Cancer Treatment
Trendline Trendline
CEL-SCI Reports Progress in Multikine Cancer Therapy Development

CEL-SCI Reports Progress in Multikine Cancer Therapy Development

CEL-SCI Reports Progress in Multikine Cancer Therapy Development
Trendline Trendline
Novartis Seeks Expansion of Pluvicto for Hormone-Sensitive Prostate Cancer

Novartis Seeks Expansion of Pluvicto for Hormone-Sensitive Prostate Cancer

Novartis Seeks Expansion of Pluvicto for Hormone-Sensitive Prostate Cancer
Trendline Trendline
Revolution Medicines' Pancreatic Cancer Drug Poised for FDA Approval, Analysts Predict Major Impact

Revolution Medicines' Pancreatic Cancer Drug Poised for FDA Approval, Analysts Predict Major Impact

Revolution Medicines' Pancreatic Cancer Drug Poised for FDA Approval, Analysts Predict Major Impact
Trendline Trendline
Tiziana Life Sciences Reports Positive Data for Intranasal Foralumab in Multiple Sclerosis Treatment

Tiziana Life Sciences Reports Positive Data for Intranasal Foralumab in Multiple Sclerosis Treatment

Tiziana Life Sciences Reports Positive Data for Intranasal Foralumab in Multiple Sclerosis Treatment
Trendline Trendline
Sensei Biotherapeutics Advances Cancer Treatment Trials with PIKTOR, Reports Financial Growth

Sensei Biotherapeutics Advances Cancer Treatment Trials with PIKTOR, Reports Financial Growth

Sensei Biotherapeutics Advances Cancer Treatment Trials with PIKTOR, Reports Financial Growth
Trendline Trendline
CEL-SCI Reports Progress in Multikine Development and Financial Results

CEL-SCI Reports Progress in Multikine Development and Financial Results

CEL-SCI Reports Progress in Multikine Development and Financial Results